Tumoricidal effects of macrophage-activating immunotherapy in a murine model of relapsed/refractory multiple myeloma

Cancer Immunology Research

Volumn 3, Issue 8, 2015, Pages 881-890

  Jensen, Jeffrey Lee ^a,b   Rakhmilevich, Alexander ^a,b   Heninger, Erika ^a,b   Broman, Aimee Teo ^a   Hope, Chelsea ^a,b   Phan, Funita ^b,c   Miyamoto, Shigeki ^b,c   Maroulakou, Ioanna ^d   Callander, Natalie ^a,b   Hematti, Peiman ^a,b   Chesi, Marta ^e   Bergsagel, P Leif ^e   Sondel, Paul ^a,b   Asimakopoulos, Fotis ^a,b  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b UNIVERSITY OF WISCONSIN   (United States)

^c UNIVERSITY OF WISCONSIN MADISON   (United States)

^d DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

^e MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G; INTERLEUKIN 12; N(G) NITROARGININE METHYL ESTER; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 9; CD40 ANTIGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MAP3K8 PROTEIN, MOUSE; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE; NFKB1 PROTEIN, MOUSE; OLIGODEOXYRIBONUCLEOTIDE; ONCOPROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; B LYMPHOCYTE; CANCER IMMUNOTHERAPY; CELL CONTACT; CELL EXPANSION; COCULTURE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOLYSIS; CYTOTOXICITY ASSAY; EX VIVO STUDY; GENOTYPE; IMMUNOPHENOTYPING; IN VITRO STUDY; IN VIVO STUDY; MACROPHAGE ACTIVATING IMMUNOTHERAPY; MACROPHAGE ACTIVATION; MULTIPLE MYELOMA; MYELOMA CELL; NATURAL KILLER T CELL; NONHUMAN; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PROTEIN ELECTROPHORESIS; TUMOR VOLUME; ANIMAL; CYTOTOXICITY; DISEASE MODEL; GENE INACTIVATION; GENETICS; HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; MACROPHAGE; METABOLISM; MORTALITY; MOUSE; NATURAL KILLER CELL; PATHOLOGY; T LYMPHOCYTE SUBPOPULATION; TUMOR RECURRENCE;

ANIMALS; ANTIGENS, CD40; CYTOTOXICITY, IMMUNOLOGIC; DISEASE MODELS, ANIMAL; GENE KNOCKOUT TECHNIQUES; HUMANS; IMMUNOTHERAPY; KILLER CELLS, NATURAL; MACROPHAGE ACTIVATION; MACROPHAGES; MAP KINASE KINASE KINASES; MICE; MULTIPLE MYELOMA; NEOPLASM RECURRENCE, LOCAL; NF-KAPPA B P50 SUBUNIT; OLIGODEOXYRIBONUCLEOTIDES; PROTO-ONCOGENE PROTEINS; T-LYMPHOCYTE SUBSETS;

EID: 84962018269     PISSN: 23266066     EISSN: 23266074     Source Type: Journal    
DOI: 10.1158/2326-6066.CIR-15-0025-T     Document Type: Article

References (50)

1. Palumbo A, Anderson K. Multiple myeloma. N Engl J Med 2011;364:1046-60.
2. Keats JJ, Chesi M, Egan JB, Garbitt VM, Palmer SE, Braggio E, et al. Clonal competition with alternating dominance in multiple myeloma. Blood 2012;120:1067-76.
3. Walker BA, Wardell CP, Melchor L, Brioli A, Johnson DC, Kaiser MF, et al. Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms. Leukemia 2014;28:384-90.
4. Kumar SK, Rajkumar SV. The current status of minimal residual disease assessment in myeloma. Leukemia 2014;28:239-40.
5. Landgren O, Gormley N, Turley D, Owen RG, Rawstron A, Paiva B, et al. Flow cytometry detection of minimal residual disease in multiple myeloma: lessons learned at FDA-NCI roundtable symposium. Am J Hematol 2014;89:1159-60.
6. Asimakopoulos F, Kim J, Denu RA, Hope C, Jensen JL, Ollar SJ, et al. Macrophages in multiple myeloma: emerging concepts and therapeutic implications. Leuk Lymphoma 2013;54:2112-21.
7. Bensinger W. Allogeneic stem cell transplantation for multiple myeloma. Hematol Oncol Clin North Am 2014;28:891-902.
8. Hope C, Ollar SJ, Heninger E, Hebron E, Jensen JL, Kim J, et al. TPL2 kinase regulates the inflammatory milieu of the myeloma niche. Blood 2014;123:3305-15.
9. Kim J, Hematti P. Mesenchymal stem cell-educated macrophages: a novel type of alternatively activated macrophages. Exp Hematol 2009;37:1445-53.
10. Martinez FO, Sica A, Mantovani A, Locati M. Macrophage activation and polarization. Front Biosci 2008;13:453-61.
11. Edwards JP, Zhang X, Frauwirth KA, Mosser DM. Biochemical and functional characterization of three activated macrophage populations. J Leukoc Biol 2006;80:1298-307.
12. Rakhmilevich AL, Alderson KL, Sondel PM. T-cell-independent antitumor effects of CD40 ligation. Int Rev Immunol 2012;31:267-78.
13. Rakhmilevich AL, Baldeshwiler MJ, Van De Voort TJ, Felder MA, Yang RK, Kalogriopoulos NA, et al. Tumor-associated myeloid cells can be activated in vitro and in vivo to mediate antitumor effects. Cancer Immunol Immunother 2012;61:1683-97.
14. Buhtoiarov IN, Sondel PM, Wigginton JM, Buhtoiarova TN, Yanke EM, Mahvi DA, et al. Anti-tumour synergy of cytotoxic chemotherapy and anti-CD40 plus CpG-ODN immunotherapy through repolarization of tumourassociated macrophages. Immunology 2011;132:226-39.
15. Wu QL, Buhtoiarov IN, Sondel PM, Rakhmilevich AL, Ranheim EA. Tumoricidal effects of activated macrophages in a mouse model of chronic lymphocytic leukemia. J Immunol 2009;182:6771-8.
16. Rakhmilevich AL, Buhtoiarov IN, Malkovsky M, Sondel PM. CD40 ligation in vivo can induce T-cell independent antitumor effects even against immunogenic tumors. Cancer Immunol Immunother 2008;57:1151-60.
17. Buhtoiarov IN, Sondel PM, Eickhoff JC, Rakhmilevich AL. Macrophages are essential for antitumour effects against weakly immunogenic murine tumours induced by class B CpG-oligodeoxynucleotides. Immunology 2007;120:412-23.
18. Lum HD, Buhtoiarov IN, Schmidt BE, Berke G, Paulnock DM, Sondel PM, et al. In vivo CD40 ligation can induce T-cell-independent antitumor effects that involve macrophages. J Leukoc Biol 2006;79:1181-92.
19. Buhtoiarov IN, Lum HD, Berke G, Sondel PM, Rakhmilevich AL. Synergistic activation ofmacrophages viaCD40and TLR9 results in T-cell independent antitumor effects. J Immunol 2006;176:309-18.
20. Buhtoiarov IN, Lum H, Berke G, Paulnock DM, Sondel PM, Rakhmilevich AL. CD40 ligation activates murine macrophages via an IFN-gammadependentmechanism resulting in tumor cell destruction in vitro. J Immunol 2005;174:6013-22.
21. Beatty GL, Chiorean EG, Fishman MP, Saboury B, Teitelbaum UR, Sun W, et al. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science 2011;331:1612-6.
22. Peng KW, Dogan A, Vrana J, Liu C, Ong HT, Kumar S, et al. Tumorassociated macrophages infiltrate plasmacytomas and can serve as cell carriers for oncolytic measles virotherapy of disseminated myeloma. Am J Hematol 2009;84:401-7.
23. Hebron E, Hope C, Kim J, Jensen JL, Flanagan C, Bhatia N, et al. MAP3K8 kinase regulates myeloma growth by cell-autonomous and non-autonomous mechanisms involving myeloma-associated monocytes/macrophages. Br J Haematol 2013;160:779-84.
24. Vougioukalaki M, Kanellis DC, Gkouskou K, Eliopoulos AG. Tpl2 kinase signal transduction in inflammation and cancer. Cancer Lett 2011;304:80-9.
25. Lopez-Pelaez M, Soria-Castro I, Bosca L, Fernandez M, Alemany S. Cot/tpl2 activity is required for TLR-induced activation of the Akt p70 S6k pathway in macrophages: implications for NO synthase 2 expression. Eur J Immunol 2011;41:1733-41.
26. Sugimoto K, Ohata M, Miyoshi J, Ishizaki H, Tsuboi N, Masuda A, et al. A serine/threonine kinase, Cot/Tpl2, modulates bacterial DNA-induced IL-12 production and Th cell differentiation. J Clin Invest 2004;114:857-66.
27. Kaiser F, Cook D, Papoutsopoulou S, Rajsbaum R, Wu X, Yang HT, et al. TPL-2 negatively regulates interferon-beta production inmacrophages and myeloid dendritic cells. J Exp Med 2009;206:1863-71.
28. Tugues S, Burkhard SH, Ohs I, Vrohlings M, Nussbaum K, Vom Berg J, et al. New insights into IL-12-mediated tumor suppression. Cell Death Differ 2015;22:237-46.
29. Chesi M, Matthews GM, Garbitt VM, Palmer SE, Shortt J, Lefebure M, et al. Drug response in a genetically engineered mouse model of multiple myeloma is predictive of clinical efficacy. Blood 2012;120:376-85.
30. McMillin DW, Delmore J, Negri JM, Vanneman M, Koyama S, Schlossman RL, et al. Compartment-Specific Bioluminescence Imaging platform for the high-throughput evaluation of antitumor immune function. Blood 2012;119:e131-8.
31. Zheng Y, Yang J, Qian J, Qiu P, Hanabuchi S, Lu Y, et al. PSGL-1/selectin and ICAM-1/CD18 interactions are involved in macrophage-induced drug resistance in myeloma. Leukemia 2013;27:702-10.
32. Kim D, Wang J, Willingham SB, Martin R, Wernig G, Weissman IL. Anti-CD47 antibodies promote phagocytosis and inhibit the growth of human myeloma cells. Leukemia 2012;26:2538-45.
33. Gantke T, Sriskantharajah S, Ley SC. Regulation and function of TPL-2, an IkappaB kinase-regulated MAP kinase kinase kinase. Cell Res 2011;21:131-45.
34. Perez-Andres M, Almeida J, Martin-Ayuso M, Moro MJ, Martin-Nunez G, Galende J, et al. Clonal plasma cells from monoclonal gammopathy of undetermined significance, multiple myeloma and plasma cell leukemia show different expression profiles of molecules involved in the interaction with the immunological bone marrow microenvironment. Leukemia 2005;19:449-55.
35. Roder J, Duwe A. The beige mutation in the mouse selectively impairs natural killer cell function. Nature 1979;278:451-3.
36. Rose S, Misharin A, Perlman H. A novel Ly6C/Ly6G-based strategy to analyze the mouse splenic myeloid compartment. Cytometry A 2012;81:343-50.
37. Gabrilovich DI, Ostrand-Rosenberg S, Bronte V. Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol 2012;12:253-68.
38. Van Rhee F, Giralt S, Barlogie B. The future of autologous stem cell transplantation in myeloma. Blood 2014;124:328-33.
39. Hart AJ, Jagasia MH, Kim AS, Mosse CA, Savani BN, Kassim A. Minimal residual disease in myeloma: are we there yet? Biol Blood Marrow Transplant 2012;18:1790-9.
40. Morgan GJ, Walker BA, Davies FE. The genetic architecture of multiple myeloma. Nat Rev Cancer 2012;12:335-48.
41. Matsui W, Borrello I, Mitsiades C. Autologous stem cell transplantation and multiple myeloma cancer stem cells. Biol Blood Marrow Transplant 2012;18(Suppl 1):S27-32.
42. Kim D, Park CY, Medeiros BC, Weissman IL. CD19 (+) CD45 (low/+) CD38 (high)/CD138 (+) plasma cells enrich for human tumorigenic myeloma cells. Leukemia 2012;26:2530-7.
43. Qian BZ, Pollard JW. Macrophage diversity enhances tumor progression and metastasis. Cell 2010;141:39-51.
44. Mantovani A, Germano G, Marchesi F, Locatelli M, Biswas SK. Cancerpromoting tumor-associated macrophages: new vistas and open questions. Eur J Immunol 2011;41:2522-5.
45. Chesi M, Robbiani DF, Sebag M, Chng WJ, Affer M, Tiedemann R, et al. AIDdependent activation of a MYC transgene induces multiple myeloma in a conditional mouse model of post-germinal center malignancies. Cancer Cell 2008;13:167-80.
46. Hussein M, Berenson JR, Niesvizky R, Munshi N, Matous J, Sobecks R, et al. A phase I multidose study of dacetuzumab (SGN-40; humanized anti-CD40 monoclonal antibody) in patients with multiple myeloma. Haematologica 2010;95:845-8.
47. Vonderheide RH, Glennie MJ. Agonistic CD40 antibodies and cancer therapy. Clin Cancer Res 2013;19:1035-43.
48. Eliopoulos AG, Wang CC, Dumitru CD, Tsichlis PN. Tpl2 transduces CD40 and TNF signals that activate ERK and regulates IgE induction by CD40. EMBO J 2003;22:3855-64.
49. Hall JP, Kurdi Y, Hsu S, Cuozzo J, Liu J, Telliez JB, et al. Pharmacologic inhibition of tpl2 blocks inflammatory responses in primary human monocytes, synoviocytes, and blood. J Biol Chem 2007;282:33295-304.
50. Demchenko YN, Glebov OK, Zingone A, Keats JJ, Bergsagel PL, Kuehl WM. Classical and/or alternative NF-kappaB pathway activation in multiple myeloma. Blood 2010;115:3541-52.